MedTrace Logo

Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Relapsing Forms of Multiple Sclerosis

NCT04909502 · Status: SUSPENDED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2022-10-21

No results posted yet for this study

Summary

The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of EHP-101 in adult subjects with Relapsing Forms of Multiple Sclerosis (RMS).

Conditions

  • Relapsing Forms of Multiple Sclerosis

Interventions

DRUG

EHP-101 25 mg OD

25 mg OD during the first 28 Days of the trial

DRUG

EHP-101 25 mg BID

25 mg BID during the first 28 Days of the trial

DRUG

EHP-101 50 mg OD

After 28 Days of treatment with 25 mg OD, patients will escalate to 50 mg OD up to the end of the trial

DRUG

EHP-101 50 mg BID

After 28 Days of treatment with 25 mg BID, patients will escalate to 50 mg BID up to the end of the trial

Sponsors & Collaborators

  • Emerald Health Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-19
Primary Completion
2023-12-31
Completion
2024-04-30
FDA Drug
Yes

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04909502 on ClinicalTrials.gov